VH
Venrock Healthcare Capital Partners III, L.P.
内部人交易记录
其他基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Explore the complete record of transactions filed by Venrock Healthcare Capital Partners III, L.P.. Insider active across 2 companies, notably KalVista Pharmaceuticals, Inc.. Cumulatively, 15 filings have been logged. Split: 14 buys · 1 sell. Total volume traded: €9.2m. History available since 27 December 2023. The latest transaction was filed on 25 March 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Venrock Healthcare Capital Partners III, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报15 总计
174,485 股@ US$16.9527.7% 占其流量Common StockSEC:0001231919-26-000286:0
25,000 股@ US$9.423.2% 占其流量Common StockSEC:0001415889-25-010587:0
574 股@ US$10.90100.0% 占其流量Common StockSEC:0001415889-25-005908:0
100,000 股@ US$9.2313.4% 占其流量Common StockSEC:0001415889-25-004324:0
73,649 股@ US$9.299.9% 占其流量Common StockSEC:0001415889-25-003665:0
43,707 股@ US$8.765.5% 占其流量Common StockSEC:0001415889-25-002809:0
4,474 股@ US$14.740.9% 占其流量Common StockSEC:0001415889-24-003118:0
88,099 股@ US$14.4717.7% 占其流量Common StockSEC:0001415889-24-002183:0
7,030 股@ US$12.731.2% 占其流量Common StockSEC:0001415889-24-001941:0
67,546 股@ US$12.5511.7% 占其流量Common StockSEC:0001415889-24-001781:0
78,925 股@ US$12.6013.7% 占其流量Common StockSEC:0001209191-24-001957:0
6,647 股@ US$12.681.2% 占其流量Common StockSEC:0001209191-24-001666:0
69,184 股@ US$12.4411.8% 占其流量Common StockSEC:0001209191-24-001403:0
17,605 股@ US$12.203.0% 占其流量Common StockSEC:0001209191-24-001008:0
41,514 股@ US$11.976.8% 占其流量Common StockSEC:0001209191-23-060015:0
About Venrock Healthcare Capital Partners III, L.P.
Venrock Healthcare Capital Partners III, L.P. is a declarant with 15 filings in total. Across the 15 sampled filings, the transactions run from 2023-12-29 to 2026-03-27, with buy volume of EUR 6659880 and sell volume of EUR 2546366, mainly in KalVista Pharmaceuticals, Inc. and Oruka Therapeutics, Inc.